This article is more than 5 years old. Information may no longer be current.

EMA committee endorses empagliflozin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boehringer Ingelheim and Eli Lilly and Company announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval of empagliflozin for blood glucose control in type 2 diabetes.

Empagliflozin is an investigational sodium glucose co-transporter 2 (SGLT2) inhibitor, and its approval was recently delayed in the U.S. by the FDA. The CHMP recommended the drug for use in treating type 2 diabetes in addition to a regimen of diet and exercise. According to the manufacturer, the drug has been investigated in 10 multinational clinical trials and in more than 13,000 adults with type 2 diabetes.

"The CHMP positive opinion brings us a step closer to having a potential new treatment option for adults in Europe with type 2 diabetes," Klaus Dugi, corporate senior vice president, medicine, at Boehringer Ingelheim, said in a press release. "If approved, empagliflozin would be the third product approved in Europe as part of the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance."